Search This Blog

Friday, May 27, 2016

Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma

Pivotal Head-to-Head ENDEAVOR Study Shows Kyprolis Plus Dexamethasone Doubled Progression-Free Survival Compared to Velcade® (Bortezomib) and Dexamethasone



Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.